It is well recognized that estrogen deficiency leads to acceleration of bone resorption and is the main trigger for postmenopausal osteoporosis. It is important to raise the peak bone mass and to inhibit the bone loss after menopause in order to prevent the postmenopausal osteoporosis. Te therapy is based on the high calcium diet and exercise therapy, and the medication is mainly by the drugs that inhibits bone resorption. Especially estrogen administration can prevent bone loss and osteoporotic fracture as well as improve vasomotor symptoms and lipid metabolism. Therefore hormone replacement therapy (HRT) will be the key medication for total care for postmenopausal women. However, HRT does not prevail in Japan due to its side effects and mental rejection. We hope that HRT will be more utilized by reducing its side effects (for example by selective estrogen receptor modulator) and by providing more information
